Testosterone Replacement in the Treatment of Advanced Prostate Cancer - Sam Denmeade and Michael Schweizer
January 7, 2020
Sam Denmeade and Michael Schweizer join Charles Ryan at the 2019 Prostate Cancer Foundation Retreat (PCF 2019) to discuss testosterone replacement in advanced prostate cancer. The three discuss the impact of testosterone on prostate cancer cells, recent clinical trials involving testosterone replacement and the risks and benefits of adding this therapy to one’s treatment plan for prostate cancer patients.
Biographies:
Sam Denmeade, MD, Co-Director Prostate Cancer Program, Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
Michael Schweizer, MD, Physician, Assistant Professor, Seattle Cancer Care Alliance, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center.
Charles J. Ryan, MD, the President and Chief Executive Officer of The Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. Charles J. Ryan is an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced prostate cancer. Dr. Ryan joined the PCF from the University of Minnesota, Minneapolis, where he served as Director of the Hematology, Oncology, and Transplantation Division in the Department of Medicine. He also served as Associate Director for Clinical Research in the Masonic Cancer Center and held the B.J. Kennedy Chair in Clinical Medical Oncology.
Biographies:
Sam Denmeade, MD, Co-Director Prostate Cancer Program, Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
Michael Schweizer, MD, Physician, Assistant Professor, Seattle Cancer Care Alliance, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center.
Charles J. Ryan, MD, the President and Chief Executive Officer of The Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. Charles J. Ryan is an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced prostate cancer. Dr. Ryan joined the PCF from the University of Minnesota, Minneapolis, where he served as Director of the Hematology, Oncology, and Transplantation Division in the Department of Medicine. He also served as Associate Director for Clinical Research in the Masonic Cancer Center and held the B.J. Kennedy Chair in Clinical Medical Oncology.
Read the Full Video Transcript